Katano Atsuto, Yamashita Hideomi, Nakagawa Keiichi
Department of Radiology, The University of Tokyo Hospital, Tokyo 113-8655, Japan.
Mol Clin Oncol. 2017 Dec;7(6):1061-1063. doi: 10.3892/mco.2017.1441. Epub 2017 Oct 4.
Stereotactic body radiation therapy (SBRT) is a safe and effective treatment for solitary cancerous lesions. The present study reported a rare case of sustained remission after SBRT for oligorecurrence in the liver in a patient with esophageal carcinoma. A 60-year-old Japanese man presented with a chief complaint of dysphagia. On medical examination, the patient was diagnosed as having squamous cell carcinoma of the esophagus that was clinically staged as T4bN1M0. The patient received definitive concurrent chemoradiotherapy, consisting of four 28-day cycles of chemotherapy comprising nedaplatin 80 mg/m on day 1 and S-1 120 mg/body orally on days 1-14, with radiotherapy comprising a total of 50 Gy in daily fractions of 2 Gy. After a 9-month disease-free interval following the primary treatment, a solitary liver metastasis was identified. The patient underwent SBRT using a radiation dose of 48 Gy in 4 fractions and two 28-day cycles of adjuvant chemotherapy comprising nedaplatin 80 mg/m on day 1, and S-1 100 mg/body orally on days 1-14. The patient exhibited no signs of recurrence for 3 years with sustained local control. SBRT may be considered a treatment option for patients with relapsed esophageal cancer with oligo-recurrence in the liver.
立体定向体部放射治疗(SBRT)是治疗孤立性癌性病变的一种安全有效的方法。本研究报告了1例食管癌患者肝寡转移灶经SBRT治疗后持续缓解的罕见病例。一名60岁日本男性因吞咽困难为主诉就诊。经医学检查,该患者被诊断为食管鳞状细胞癌,临床分期为T4bN1M0。患者接受了根治性同步放化疗,包括4个28天周期的化疗,第1天给予奈达铂80mg/m²,第1 - 14天口服S-1 120mg/体,放疗总量为50Gy,每日分次剂量为2Gy。在初始治疗后的9个月无病间期后,发现了1个孤立性肝转移灶。患者接受了SBRT,放射剂量为48Gy分4次给予,并接受了2个28天周期的辅助化疗,第1天给予奈达铂80mg/m²,第1 - 14天口服S-1 100mg/体。患者3年无复发迹象,局部持续控制良好。SBRT可被视为肝寡转移复发食管癌患者的一种治疗选择。